ClinicalTrials.gg
RecruitingNCT04781634Updated Feb 25, 2025

A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

A Phase 1/2 interventional study of CD19 and CD22 targeted prime CAR-T cells in B-ALL, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 2 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-25.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
2 Years to 75 Years
Sex
All
01

Study summary

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL

Read the detailed description

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies.

There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, the investigators launch such a clinical trial using CD19 and CD22 targeted prime CAR-T cells for patients with relapsed and refractory B-ALL to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cell therapy.

02

Conditions studied

  • B-ALL

Keywords

  • CD19
  • CD22
  • CAR-T
03

In context

Lead sponsor

Chongqing Precision Biotech Co., Ltd is the lead sponsor of 51 studies on the registry; 37 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed written
  2. Diagnose as B -ALL, and meet one of the following conditions:

    1. Failed to standard chemotherapy regimens;
    2. Relapse after complete remission, high-risk and / or refractory patients ;
    3. Relapse after hematopoietic stem cell transplantation;
  3. For patients with Ph + ALL, the following conditions must be met: those who have received a standard induction chemotherapy regimen and who have not achieved complete remission after TKI treatment or have relapsed after remission (cannot tolerate TKI treatment or have to TKI treatment or the presence of TKI class) Except for drug resistant patients)
  4. Evidence for cell membrane CD19 or CD22 expression
  5. All genders ages: 2 to 75 years
  6. The expect time of survive is above 3 months;
  7. >60
  8. No serious mental disorders ;
  9. ≥50%
  10. Sufficient hepatic function defined by /AST≤3 x and ≤2 x ULN;
  11. Sufficient renal function defined by ≤2 x ULN;
  12. Sufficient pulmonary function defined by indoor oxygen saturation≥92%;
  13. With single or venous blood collection standards, and no other cell collection contraindications;
  14. Ability and willingness to adhere to the study visit schedule and all protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of other ;
  2. Presence of uncontrolled active infection;
  3. Evidence of disorder that need the treatment by ;
  4. Active or chronic
  5. The patients treatment by inhibitor of T cell
  6. Pregnant or breasting-feeding women;
  7. Any situation that investigators regard not suitable for attending in this study (e.g. , HCVinfection or intravenous drug addiction) or may affect the data analysis.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    prime CAR- T cells

    Patients will be be treated with CD19 and CD22 prime CAR- T cells

    Biological: CD19 and CD22 targeted prime CAR-T cells

Interventions

  • BiologicalCD19 and CD22 targeted prime CAR-T cells

    A single infusion of CD19 and CD22 prime CAR-T cells will be administered intravenously

06

What researchers measure

Primary outcomes

  1. Adverse events that related to treatment

    Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)

    Time frame: 2 years

  2. The response rate of CD19 and CD22 prime CAR-T treatment in patients with relapse/refractory B-ALL

    The response rate of CD19 and CD22 prime CAR-T treatment will be recorded and assessed according to the National Comprehensive Cancer Network Guideline

    Time frame: 6 months

Secondary outcomes

  1. Rate of prime CAR-T cells in bone marrow

    Determine the rate of prime CAR-T cells in bone marrow by flow cytometry

    Time frame: 2 years

  2. Rate of prime CAR-T cells in peripheral blood

    Determine the rate of prime CAR-T cells in peripheral blood by flow cytometry

    Time frame: 2 years

  3. Quantity of prime CAR copies in bone marrow

    Determine the quantity of prime CAR copies in bone marrow by qPCR

    Time frame: 2 years

  4. Quantity of prime CAR copies in peripheral blood

    Determine the quantity of prime CAR copies in peripheral blood by qPCR

    Time frame: 2 years

  5. Rate of CD19 and CD22 positive cells in Bone marrow

    Determine the rate of CD19 and CD22 positive cells in bone marrow by flow cytometry

    Time frame: 1 years

  6. Levels of IL-6 in Serum

    Serological determination of IL-6

    Time frame: 3 months

  7. Levels of IL-10 in Serum

    Serological determination of IL-10

    Time frame: 3 months

  8. Levels of TNF-α in Serum

    Serological determination of TNF-α

    Time frame: 3 months

  9. Levels of CRP in Serum

    Serological determination of CRP

    Time frame: 3 months

  10. Duration of Response (DOR) of CD19 and CD22 prime CAR-T treatment in patients with refractory/relapsed B-ALL

    DOR will be assessed from the first assessment of CR/CRi to the first assessment of recurrence or progression of the disease or death from any cause (censored)

    Time frame: 2 years

  11. Progress-free survival(PFS) of CD19 and CD22 targeted prime CAR-T treatment in patients with refractory/relapsed B-ALL

    PFS will be assessed from the first prime CAR-T cell infusion to death from any cause or the first assessment of progression (censored)

    Time frame: 2 years

  12. Overall survival(OS) of CD19 and CD22 prime CAR-T treatment in patients with refractory/relapsed B-ALL

    OS will be assessed from the first primeCAR-T cell infusion to death from any cause (censored)

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 4, 2021
StartActual
Mar 7, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jul 1, 2027
Last update
Feb 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04781634
Responsible party
Sponsor
First posted
Mar 4, 2021
Start date
Mar 7, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Feb 25, 2025

Study contacts

Zhi Yang, PhD
Contact
yangzhi@precision-biotech.com
86-13206140093
Sanbin Wang, MD
Contact
Sanbin1011@163.com
Sanbin Wang, MD
principal investigator · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Cheng Qian, PhD
principal investigator · Chongqing University Cancer Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion